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A B S T R A C T
Accumulating evidence suggests that a degenerative processes within the brain can trigger the formation of new,
focal inflammatory lesions in Multiple Sclerosis (MS). Here, we used a novel pre-clinical MS animal model to test
whether the amelioration of degenerative brain events reduces the secondary recruitment of peripheral immune
cells and, in consequence, inflammatory lesion development.
Neural degeneration was induced by a 3 weeks cuprizone intoxication period. To mitigate the cuprizone-
induced pathology, animals were treated with Laquinimod (25mg/kg) during the cuprizone-intoxication period.
At the beginning of week 6, encephalitogenic T cell development in peripheral lymphoid organs was induced by
the immunization with myelin oligodendrocyte glycoprotein 35–55 peptide (i.e., Cup/EAE). Demyelination,
axonal injury and reactive gliosis were determined by immunohistochemistry. Positron emission tomography
(PET) imaging was performed to analyze glia activation in vivo.
Vehicle-treated cuprizone mice displayed extensive callosal demyelination, glia activation and enhanced
TSPO-ligand binding. This cuprizone-induced pathology was profoundly ameliorated in mice treated with
Laquinimod. In vehicle-treated Cup/EAE mice, the cuprizone-induced pathology triggered massive peripheral
immune cell recruitment into the forebrain, evidenced by multifocal perivascular inflammation, glia activation
and neuro-axonal injury. While anti myelin oligodendrocyte glycoprotein 35–55 peptide immune responses were
comparable in vehicle- and Laquinimod-treated Cup/EAE mice, the cuprizone-triggered immune cell recruitment
was ameliorated by the Laquinimod treatment.
This study clearly illustrates that amelioration of a primary brain-intrinsic degenerative process secondary
halts peripheral immune cell recruitment and, in consequence, inflammatory lesion development. These findings
have important consequences for the interpretation of the results of clinical studies.
1. Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating
disease of the central nervous system (CNS) causing disability in> 2.5
million people worldwide. On the histopathological level, brains of MS
patients show perivascular inflammation, peripheral immune cell re-
cruitment, demyelination, glia activation and axonal injury. Of note,
the demyelination is not restricted to the white matter but can as well
be found in the cortical and subcortical grey matter areas (Di Filippo
et al., 2018; Kipp et al., 2012; Schmierer et al., 2018). Besides such
focal lesions, diffuse tissue injury is characteristic for the MS brain.
Diffuse tissue injuries in non-lesion containing brain areas has been
demonstrated by various techniques including gene expression ana-
lyses, in situ hybridization, immunofluorescence studies (Aboul-Enein
et al., 2003; Zeis et al., 2008), or by different imaging modalities such
as proton magnetic resonance spectroscopic imaging (Fu et al., 1998) or
Gadolinium enhanced magnetic resonance imaging (Silver et al., 2001).
Since such areas of diffuse tissue injury do not show the ‘classical de-
myelination’ such affected areas are called ‘normal appearing white and
grey matter’. Clinically, MS can be categorized into three main groups:
relapsing-remitting, secondary progressive, and primary progressive.
While the pathological substrate of relapses is the focal, inflammatory
demyelination, irreversible disease progression is due to neuroaxonal
damage (i.e., neurodegeneration). Despite the availability of a number
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of immunomodulatory drugs, which are mostly effective during the
relapsing-remitting disease phase, there are no entirely satisfactory
treatment options for secondary progressive and primary progressive
MS patients.
Laquinimod, formerly called ABR-215062, is a small molecule de-
veloped as an orally available disease modifying treatment option in
MS. This drug inhibits the development of disease in inflammatory
mouse models for MS, such as experimental autoimmune en-
cephalomyelitis (EAE) and experimental autoimmune neuritis (Thone
et al., 2012; Yang et al., 2004; Zou et al., 2002). Laquinimod was
equally protective in non-inflammatory CNS-disease models such as the
cuprizone model (Bruck et al., 2012; Kramann et al., 2016), models of
Huntigton disease (Ellrichmann et al., 2017; Garcia-Miralles et al.,
2019) or traumatic brain injury (Katsumoto et al., 2018). Beyond, it has
been shown that Laquinimod can regulate synaptic transmission by
increasing inhibitory GABAergic post-synaptic currents, can reduce
glutamatergic excitatory post-synaptic currents (Ruffini et al., 2013),
and improve axonal remyelination and integrity in EAE (Moore et al.,
2013). These and other findings suggest immunomodulatory, neuro-
protective and neurorestorative effects of Laquinimod. Two in-
dependent clinical studies demonstrated that Laquinimod is effective in
suppressing the development of active lesions in relapsing-remitting MS
(Comi et al., 2008; Polman et al., 2005). With respect to its neuropro-
tective function, two subsequent placebo-controlled studies in relap-
sing-remitting MS showed significant reductions in brain atrophy by
Laquinimod versus placebo (Comi et al., 2012; Vollmer et al., 2014).
Evidence for a direct neuroprotective effect was as well reported in a
follow-up imaging study (Filippi et al., 2014). Taken together, it is
likely that Laquinimod combines anti-inflammatory and neuroprotec-
tive properties.
One major drawback for translational MS research is what we call
the “clinical-preclinical discrepancy”. Inflammatory activity and CNS
atrophy is, during most clinical studies, analyzed in the brain (i.e., in
the forebrain/prosencephalon, the midbrain/mesencephalon and the
hindbrain/rhombencephalon). In contrast, in classical EAE models (i.e.,
MOG35–55-induced EAE in C57BL/6 mice) inflammatory lesions pre-
dominantly develop within the spinal cord and cerebellum, whereas
other parts of the CNS are by far less severely affected. A model
showing robust inflammatory lesion development in the forebrain
would, thus, be valuable to study MS related pathologies and treatment
effects. Our group and others recently demonstrated that primary oli-
godendrocyte degeneration, induced by cuprizone intoxication, can
trigger peripheral immune cell recruitment into the forebrain after
MOG35–55 immunization (Baxi et al., 2015; Boretius et al., 2012; Ruther
et al., 2017; Scheld et al., 2016). In the Scheld study, forebrain oligo-
dendrocyte apoptosis was first induced by a 3-week intoxication with
cuprizone, followed by the induction of encephalitogenic T-cell for-
mation in peripheral lymphoid organs via the immunization with the
myelin oligodendrocyte glycoprotein 35–55 peptide (MOG35–55+ CFA/
PTX; i.e., the induction of active EAE) at the beginning of week 6. This
innovative model provides an excellent tool to study inflammatory le-
sion development and progression within the forebrain of mice. Fur-
thermore, it allows to investigate the cell-cell communication pathways
operant during CNS-triggered immune cell recruitment.
During the current study we, first, aimed to analyze whether
Laquinimod ameliorates cuprizone-induced demyelination. Second, we
were interested whether the Laquinimod-mediated amelioration of cu-
prizone-induced pathologies reduces the secondary recruitment of
peripheral immune cells into the forebrain and, in consequence, in-
flammatory lesion development.
2. Material and methods
2.1. Animals and experimental groups
C57BL/6 female mice at 8 wks of age were obtained from Janvier
Labs, Le Genest-Saint-Isle, France. All experimental procedures were
approved by the Review Board for the Care of Animal Subjects of the
district government (Regierung Oberbayern; reference number 55.2-
154-2532-73-15; Germany). A maximum of five animals were housed
per cage (435 cm2). Animals were kept under standard laboratory
conditions (12 h light/dark cycle, controlled temperature 23 °C ± 2 °C
and 50% ± 5% humidity) with access to food and water ad libitum.
The mice were allowed to accommodate to the environment for at least
one week prior to the beginning of the experiments and were provided
with nestlets for environmental enrichment. Body weights of mice were
controlled once per week. The mice were randomly assigned to the
experimental groups as illustrated in supplementary Fig. 1. (A) Control,
animals were provided a diet of standard rodent chow for the entire
duration of the study. (B) Cup/Vehicle, the animals were intoxicated
with a diet containing 0.25% cuprizone for three weeks, followed by
two weeks of normal chow. A vehicle solution was administered daily
by oral gavage (200 μl) during week 1–3. (C) Cup/Laquinimod, the
animals were intoxicated with a diet containing 0.25% cuprizone for
Table 1
List of the primary antibodies used in this study.
Antigen Species Dilution HIER method Purchase number RRID Supplier
IBA1 rabbit 1:5000 Tris/EDTA 019-19741 AB_839504 Wako, USA
MAC3 rat 1:200 Tris/EDTA 550292 AB_393587 BD Pharmingen
Vimentin rabbit 1:200 Tris/EDTA ab92547 AB_10562134 Abcam, UK
GFAP chicken 1:8000 Citrate ab4674 AB_304558 Abcam, UK
ALDH1L1 rabbit 1:1000 None ab87117 AB_10712968 Abcam, Uk
CD4 rabbit 1:1000 Tris/EDTA ab183685 AB_2686917 Abcam, UK
APP mouse 1:5000 Tris/EDTA MAB348 AB_94882 Millipore, USA
VGluT1 mouse 1:1000 Citrate ab134283 not available Abcam, UK
Synaptophysin mouse 1:300 Citrate ab8049 AB_2198854 Abcam, UK
Table 2
List of the secondary antibodies used in this study.
Dilution Order number RRID Supplier
Goat anti-rabbit IgG 1:200 BA-1000 AB_2313606 Vector Laboratories, Burlingame, USA
Goat anti-rat IgG 1:200 BA-9400 AB_2336202 Vector Laboratories, Burlingame, USA
Goat anti-chicken IgG 1:200 BA-9010 AB_2336114 Vector Laboratories, Burlingame, USA
Goat anti-mouse IgG 1:200 BA-9200 AB_2336171 Vector Laboratories, Burlingame, USA
HRP-linked goat anti-mouse IgG 1:1 K4001 not available Dako, Santa Clara, USA
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three weeks, followed by two weeks of normal chow. A Laquinimod
solution was administered daily by oral gavage (200 μl; 25mg/kg)
during week 1–3. (D) CupEAE/Vehicle, animals were intoxicated with
cuprizone and treated with vehicle solution as described for group B. At
the beginning of week six, the mice were immunized with MOG35–55
peptide as published previously (Ruther et al., 2017; Scheld et al.,
2016). (E) CupEAE/Laquinimod, animals were intoxicated with cupri-
zone and treated with Laquinimod solution as described for group C. At
the beginning of week six, the mice were immunized with MOG35–55
peptide. Laquinimod was provided from Teva Pharmaceutical In-
dustries, LTd., Petah Tikva, Israel and was dissolved at 2.5mg/ml in
purified water. The dosing regimen was selected based on a previous
report (Wegner et al., 2010).
2.2. Cuprizone intoxication and EAE induction
To induce neurodegeneration of the forebrain, mice were in-
toxicated with the copper chelator Cuprizone (bis(cyclohexanone)ox-
aldihydrazone; Sigma-Aldrich, Taufkirchen, Germany) as previously
published by our group (Hochstrasser et al., 2017; Slowik et al., 2015).
In brief, 0.25 g cuprizone was weighed using precision scales and me-
chanically mixed with 100 g ground standard rodent chow using a
commercial available kitchen machine (Kult X, WMF Group, Geislingen
an der Steige, Germany). The chow was mixed at low speed and manual
agitation for 1min and was provided within the cage in two separate
plastic Petri dishes.
The formation of myelin autoreactive T cells was achieved by im-
munization with an emulsion of Myelin oligodendrocyte glycoprotein
(MOG) peptide dissolved in complete Freund's adjuvant (CFA), fol-
lowed by intraperitoneal injection of pertussis toxin (PTX) in phos-
phate-buffered saline (PBS), first on the day of immunization and then
again the following day (i.e., active EAE). A ready-to-use kit provided
by Hooke Laboratories was used. Scoring of disease severity was per-
formed daily as published previously (Barthelmes et al., 2016; Beeton
et al., 2007) as follows: A score of 0.5 was assigned if the tip of the tail
was limb when the mouse was picked up by the base of the tail; a score
of 1 was assigned if the entire tail dropped over the finger of the ob-
server when the mouse was picked up by the base of the tail; when the
mouse was dropped on a wire rack, and at least one hind leg fell
through consistently, a score of 1.5 was given; a score of 2 was assigned
when the legs of the mice were not spread apart but held close together
when the mouse was picked up by the base of the tail, or when the mice
exhibited a clearly apparent wobbly gait; a score of 2.5 was assigned
when the tail was limp and both hind legs had movement, but were
dragging at the feet, or one hind leg showed complete paralysis,
whereas the other one still showed movement; a score of 3 was assigned
when the tail was limp and the mice showed complete paralysis of hind
legs; a score of 3.5 was given if the mouse was unable to raise itself
when placed on its side; a score of 4 was assigned if the tail was limp
and the mice showed complete hind leg and partial front leg paralysis,
and the mouse was minimally moving around the cage but appeared
alert; a score of 4.5 was given if the mouse showed no movement
around the cage and appeared not alert.
2.3. Tissue preparation
Mice were deeply anaesthetized with ketamine (100mg/kg i.p.) and
xylazine (10mg/kg i.p.) and transcardially perfused with ice-cold PBS
followed by a 3.7% paraformaldehyde solution (PFA; pH 7.4). The
brains and spinal cords were postfixed in the same fixative at 4 °C,
carefully dissected and embedded in paraffin. Then, sections of 5 μm
were prepared for histological investigations. Brains were sectioned at
the levels 215 up to 265 according to the mouse brain atlas by Sidman
et al. (http://www.hms.harvard.edu/research/brain/atlas.html).
Region 215 corresponds to the stereotaxic coordinates Bregma +0.14,
whereas region 265 corresponds to the stereotaxic coordinates Bregma
−1.01, provided by Franklin and Paxinos.
2.4. Histology and immunohistochemistry
For histological evaluations, randomly selected brain sections con-
taining the region of interest (ROI) were stained with standard Luxol
fast blue-periodic acid-Schiff (LFB/PAS) to determine demyelination,
and hematoxylin & eosin (H&E) to quantify the number and spatial
distribution of perivascular infiltrates within the forebrain. Spinal cord
sections were stained with LFB/PAS to evaluate inflammatory demye-
lination within the white matter.
Immunohistochemistry was performed using the following anti-
bodies: Anti-Ionized calcium-binding adaptor molecule 1 (IBA1) and
anti-MAC3 to visualize microglia and macrophages, anti-Vimentin,
anti-glial fibrillary acidic protein (GFAP) and anti-Aldehyde
Dehydrogenase 1 Family Member L1 (ALDH1L1) to study the signature
of astrocyte activation, anti-CD4 to visualize T-helper cells, and anti-
amyloid precursor protein (APP), anti-vesicular glutamate transporter 1
(vGLUT1) and anti-Synaptophysin to detect acutely damaged axons.
The stains were conducted following established protocols (Nyamoya
et al., 2019; Ruther et al., 2017). In brief, the sections were rehydrated,
and if necessary, antigens were unmasked by heating in either Tris/
EDTA (pH 9.0) or citrate (pH 6.0) buffer. After washing in PBS, un-
specific binding sites were blocked in blocking solution (serum of the
species in which the secondary antibody was produced) for 1 h. Then,
the sections were incubated overnight (at 4 °C) with the primary anti-
bodies diluted in blocking solution. The next day, the slides were
treated with 0.3% hydrogen peroxide in PBS for 30min. After washing
in PBS, the slides were incubated with biotinylated secondary anti-
bodies for 1 h and then with peroxidase-coupled avidin-biotin complex
(ABC kit; Vector Laboratories, Peterborough, UK). Anti-vGLUT1 and
anti-Synaptophysin stains were performed using HRP-linked goat anti-
mouse IgG secondary antibodies (Dako, Germany). The primary and
secondary antibodies used in this study are listed in Tables 1 and 2.
Finally, the sections were treated with 3,3′-diaminobenzidine (DAKO,
Hamburg, Germany) as a peroxidase substrate. Appropriate negative
controls (without primary antibodies or with isotype antibodies) were
performed in parallel as previously described (Baertling et al., 2010) to
ensure specificity of the staining.
2.5. Histological evaluations
All analyses were performed with coronal sections at the levels
R215 and R265 using a Nikon ECLIPSE 50i microscope (Nikon
Instruments, Düsseldorf, Germany) equipped with a DS-2Mv camera.
The following ROIs were defined: midline of the corpus callosum (CC),
lateral corpus callosum, subcortex, and primary somato-sensory cortex.
To estimate demyelination in LFB/PAS stains, a nonparametric grading
Fig. 1. Laquinimod ameliorates cuprizone-induced demyelination and microgliosis.
(A) Representative LFB/PAS stains of the lateral CC (region 215; left) and midline of the CC (region 265; right). Arrows highlight the lateral part of the CC in region
215. (B/C) Extent of demyelination, determined in LFB/PAS stained sections (R215 in B and R265 in C; control: n=5, Cup-Veh: n=10, Cup-Laq: n= 10).
Differences were determined using Kruskal-Wallis-Test, followed by Dunn's multiple comparisons test. (D) Representative anti-IBA1 stained sections of the lateral CC
(region 215; left) and midline of the CC (region 265; right). Arrows highlight the lateral part of the CC in region 215. (E/F) Extent of microglia/monocyte reactivity,
determined in IBA1-stained sections (R215 in E and R265 in F; control: n= 5, Cup-Veh: n=10, Cup-Laq: n=10). Differences were determined using one-way
ANOVA followed by Tukey's multiple comparisons test.
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approach was performed by two independent and blinded evaluators. In
region 215, the lateral CC was defined as ROI and the slides were scored
on a scale from 1 (normal myelination) to 5 (most severe demyelina-
tion; see supplementary Fig. 2A). In region 265, the midline of the CC
was defined as the ROI and the slides were sorted by one blinded
evaluator in ascending order of the extent of demyelination. In H&E-
stains, the number of perivascular infiltrates within the forebrain was
quantified between the levels 215 and 265 by two blinded observers
and the results were averaged. To analyze cell/spheroid densities in
immunohistochemically processed sections, the ROI-area was manually
outlined using ImageJ (NIH, Bethesda, MD, USA), and positive cells
were counted by at least two evaluators blinded to the treatment
groups. The results were averaged and are shown as cells/mm2. Since
defining individual cells in the fully demyelinated corpus callosum was
sometimes challenging (mainly at the level R265), in some cases
staining intensities were quantified by densitometrical analyses.
Therefore, binary-converted pictures were evaluated within the ROI
using ImageJ. A value of 100% represents a maximum and 0% a
minimum of staining intensity. Results are shown as staining intensity
in [%] Area of the entire ROI.
Spinal cord sections were stained with LFB/PAS to visualize intact
and damaged myelin plus inflammatory infiltrates. The extent of in-
flammatory demyelination was quantified by measuring an in-
flammatory-demyelination index, which is defined as the area covered
by inflammatory demyelination in relation to the entire white matter
area of each slide (see supplementary Fig. 2B). The index was measured
in two slides per animal by two different observers, and then averaged.
2.6. Positron emission tomography (PET)—imaging
Four mice per group of controls, Cup/Veh and Cup/Laquinimod
underwent PET after week 5 of the experimental setup. All rodent PET
procedures followed an established standardized protocol for radio-
chemistry, acquisition and post-processing (Brendel et al., 2016;
Overhoff et al., 2016). In brief, [18F]-GE-180 TSPO-PET
(11.8 ± 2.2MBq) with an emission window of 60–90min p.i. was used
to measure cerebral glial activity by a Siemens Inveon DPET (Siemens,
Knoxville, Tennessee). All analyses were performed using PMOD (V3.5,
PMOD technologies, Basel, Switzerland). Normalization of the injected
activity was performed by the previously validated myocardium cor-
rection method (Deussing et al., 2018). TSPO-PET values, deriving from
predefined volumes of interest (VOI; medial corpus cal-
losum=7.7mm3, analogous to the R265 ROI and bihemispheric lateral
corpus callosum=3.7mm3 each, analogous to the R215 ROI) were
extracted and compared between the groups.
2.7. Statistical analyses
All data are given as arithmetic means± SEMs. Differences between
groups were statistically tested using Prism 5 (GraphPad Software Inc.,
San Diego, CA, USA). p-values of< 0.05 were considered to be statis-
tically significant. The following symbols are used to indicate the level
of significance: *p < .05, **p < 0.01, ***p < 0.001, ns indicates ‘not
significant’. No outliers were excluded from the analyses. The Shapiro-
Wilk test was applied to test for normal data distribution. Applied
statistical tests are given in the respective figure legends.
3. Results
It has previously been shown that Laquinimod ameliorates anti
MOG35–55 immune responses in EAE mice (Kaye et al., 2016). First, we
were interested whether Laquinimod is as well protective in a model of
metabolic oligodendrocyte injury. To this end, mice were intoxicated
with cuprizone for three weeks, and thereafter put on normal chow for
another two weeks. During the three weeks cuprizone intoxication
period, one group was treated with vehicle solution (group B in sup-
plementary Fig. 1), and another group was treated daily with Laqui-
nimod (25mg/kg; group C). After week 5, the mice were sacrificed and
their brains were analyzed for demyelination and the activation of
microglia cells at two distinct brain levels (i.e., R215 and R265).
At the levels of the anterior commissure (i.e., R215) a severe loss of
LFB-staining intensity, suggestive for demyelination, was observed in
the lateral parts of the corpus callosum (see Fig. 1A, left column and
Fig. 1B), whereas at the level of the rostral hippocampus (i.e., R265; see
Fig. 1A, right column and Fig. 1C) LFB-staining intensity loss was severe
within medial parts of the corpus callosum. Demyelination was paral-
leled by the accumulation of IBA1+ microglia which was particularly
pronounced at the level of the rostral hippocampus (Fig. 1D–F). Both
cuprizone-induced pathologies were significantly ameliorated by the
Laquinimod-treatment. To verify reduced microglia activities in La-
quinimod-treated mice, serial sections were processed for anti-MAC3
immunohistochemistry, which labels activated microglia cells and
monocytes. As demonstrated in Fig. 2A–C, at both brain levels pro-
nounced anti-MAC3 staining intensity was observed in vehicle- but not
Laquinimod-treated cuprizone mice. Furthermore, Laquinimod pre-
vented cuprizone-induced astrocyte activation, as demonstrated by
anti-GFAP, anti-Vimentin and anti-ALDH1L1 immunohistochemistry
(see Fig. 2D), respectively. To further substantiate the finding of a
protective Laquinimod effect in the cuprizone model, activated micro-
glia and astrocytes were additionally visualized by [18F]-GE-180-PET
imaging as described recently by our group (Nack et al., 2019). As
demonstrated in Fig. 2E, we found a significant increase of [18F]-GE180
uptake in the medial and lateral corpus callosum of Cup/Veh but not
Cup/Laq mice. In summary, these results clearly show that Laquinimod
almost completely ameliorates the cuprizone-induced myelin pa-
thology.
To understand, whether the observed protective effect of
Laquinimod in the cuprizone model results in less severe peripheral
immune cell recruitment if encephalitogenic T cells are induced in the
peripheral lymphoid organs, in a next step we repeated the experiments
as described above but immunized both cohorts at the beginning of
week 6 with MOG35–55 peptide dissolved in CFA+PTX (i.e., active EAE
induction; groups D and E in supplementary Fig. 1). Of note, peripheral
immune cells do not invade the forebrain in classical MOG35–55-induced
EAE (Ruther et al., 2017; Scheld et al., 2016). First, we verified that
active MOG35–55 induces a comparable active immune response in
Fig. 2. Laquinimod ameliorates cuprizone-induced gliosis.
(A) Representative anti-MAC3 stains of the lateral CC (region 215; left) and midline of the CC (region 265; right). Arrows highlight the lateral part of the CC in region
215. (B/C) Extent of microglia activation, determined in anti-MAC3 stained sections (R215 in B and R265 in C; control: n=5/4, Cup-Veh: n=9/11, Cup-Laq:
n= 10/10). Differences were determined using Kruskal-Wallis-Test followed by Dunn's multiple comparisons test. (D) Extent of astrocyte activation, determined in
anti-GFAP (upper graph), anti-Vimentin (middle graph) or anti-ALDH1L1 (lower graph) processed sections (control: n= 5, Cup-Veh: n=11, Cup-Laq: n= 10).
Differences for anti-GFAP and anti-ALDH1L1 stains were determined using one-way ANOVA followed by Tukey's multiple comparisons test. Differences for anti-
Vimentin stains were determined using Kruskal-Wallis-Test followed by Dunn's multiple comparisons test. (E) Quantification of [18F]-GE-180 radioligand uptake in
control, Cup-Veh and Cup-Laq mice (n=4 animals per group). Averaged normalized radioligand uptake per group is shown for the lateral CC (region 215; upper
row) and for the midline of the CC (region 265; lower row). Coronal slices are depicted upon an MRI atlas. Differences for [18F]-GE-180 radioligand uptake values
were determined using Kruskal-Wallis-Test followed by Dunn's multiple comparisons test. Please note that activity spilling into the hypothalamus is related to
unspecific uptake in the hypophysis. The unspecific binding has to be considered when regions adjacent to the hypophysis are considered for evaluation but it had no
impact on the current analysis.
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vehicle and Laquinimod-treated mice. As shown in Fig. 3A–D, the se-
verity of clinical symptoms was comparable in both genotypes. In
particular, no significant difference was observed for the parameters
day of disease onset (CupEAE-Veh 10.5 ± 2.5 vs. CupEAE-Laq
11.5 ± 1.6; p=0.25), cumulative disease score (CupEAE-Veh
10.0 ± 6.0 vs. CupEAE-Laq 7.2 ± 4.7; p=0.28) and maximum dis-
ease score (CupEAE-Veh 2.6 ± 1.2 vs. CupEAE-Laq 2.9 ± 1.1;
p=0.68). In line with this finding, there was no significant difference
in the extent of inflammatory infiltrates in the spinal cord of CupEAE-
Veh vs. CupEAE-Laq mice (Fig. 3E–F). Next, we analyzed the forebrain
at distinct rostral-to-caudal levels for the presence of perivascular in-
filtrates, a hallmark of active MS lesions. In line with previous ob-
servations, several perivascular infiltrates were present in the fore-
brains of CupEAE-Veh animals. Such infiltrates were topographically
distributed widely, including the cortex, CC and subcortical regions
(Fig. 3G). Remarkably, the number of perivascular infiltrates was sig-
nificantly lower in CupEAE-Laq compared to CupEAE-Veh animals
(Fig. 3H). Whereas in CupEAE-Veh animals the average number of
perivascular cuffs per slide was 3.4 ± 2.9, CupEAE-Laq animals con-
tained 0.7 ± 0.9 perivascular cuffs per slide (p≤0.0001). To sub-
stantiate our finding of less severe peripheral immune cell recruitment
in the CupEAE-Laq group, brain sections were processed for anti-CD4
immunohistochemistry to label Th-lymphocytes. Densities of CD4+
lymphocytes were significantly increased in CupEAE-Veh but not Cu-
pEAE-Laq mice. Lower CD4+ cell densities in Laquinimod-treated mice
were found at various topographical sites including the corpus callosum
(Fig. 3I/J), cortex and subcortex (data not shown).
Finally, we were interested whether neurodegeneration is amelio-
rated in Laquinimod-treated CupEAE mice. The extent of acute axonal
injury was analyzed by quantifying the densities of axonal swellings in
anti-APP stained sections. As demonstrated in Fig. 4A–C, APP+ spher-
oids were virtually absent in control animals, whereas numerous were
found in CupEAE/Veh mice. Of note, just some APP+ spheroids were
observed in CupEAE-Laq mice. To substantiate this observation, we
additionally stained sections of CupEAE-Veh and CupEAE-Laq mice
against the vesicular glutamate transporter 1 (vGLUT1) and Synapto-
physin, also known as the major synaptic vesicle protein p38. As re-
cently shown, both synaptic proteins accumulate as spheroids within
acutely injured axons (Gudi et al., 2017; Ruhling et al., 2019). As de-
monstrated in Fig. 4D–G, high densities of vGLUT1+ and Synapto-
physin+ spheroids were found in CupEAE-Veh but not CupEAE-Laq
mice. These data clearly demonstrate a neuroprotective effect of La-
quinimod in the applied model.
4. Discussion
In this study, we demonstrated that oral Laquinimod treatment
ameliorates inflammatory demyelination and neurodegeneration in a
novel MS animal model which is characterized by multi-focal perivas-
cular inflammation in the entire CNS, most importantly in the forebrain
(Chrzanowski et al., 2019; Ruther et al., 2017; Scheld et al., 2016).
Furthermore, we verified previous findings demonstrating that Laqui-
nimod prevents cuprizone-induced demyelination (Bruck et al., 2012;
Kramann et al., 2016).
Our group and others recently demonstrated that primary
oligodendrocyte degeneration can trigger peripheral immune cell re-
cruitment into the forebrain in MOG35–55 immunized mice (Baxi et al.,
2015; Boretius et al., 2012; Ruther et al., 2017; Scheld et al., 2016). In
these studies, oligodendrocyte apoptosis in the brains of mice was first
induced by a 3-week intoxication with cuprizone, and an infiltration of
myelin autoreactive T cells from peripheral lymphoid organs was then
triggered via immunization with the MOG35–55 peptide. In the current
study we were now interested to see whether amelioration of the cu-
prizone-induced pathology by Laquinimod results in less severe sec-
ondary peripheral immune cell recruitment.
Our observation of a strong protective Laquinimod effect in the
cuprizone model is in line with previous observations. Brück and col-
leagues nicely demonstrated that Laquinimod prevents cuprizone-in-
duced demyelination, microglial activation and axonal degeneration
(Bruck et al., 2012; Kramann et al., 2016). Further mechanistic studies
suggested that the protective effect of Laquinimod in the cuprizone
model is mediated by a modulation of astrocyte function, in particular
by attenuating astrocytic NF-κB activation. We verify the observation of
a protective Laquinimod effect in the cuprizone model but additionally
show that the pharmacological amelioration of the cuprizone-induced
pathology secondary results in less severe peripheral immune cell re-
cruitment. This important and novel finding suggests that therapeutic
strategies, which ameliorate brain intrinsic inflammatory responses
(i.e., astrocyte and/or microglia activation), at the same time can de-
crease the recruitment of peripheral immune cells, in particular lym-
phocytes. Histopathological studies revealed that during progressive
MS, T and B cells can still be found within the CNS parenchyma, and
that the densities of T- and B-cells positively correlate with the level of
acute axonal injury (Frischer et al., 2009). Understanding the relation
between inflammation and neurodegeneration is of key importance for
future therapeutic strategies in MS. If inflammation drives subsequent
neurodegeneration, proper anti-inflammatory therapies are the best
choice to stop the disease and to prevent further clinical deterioration
of the patients. Results of this study, however, suggest that the opposite
might equally be true: Amelioration of brain-intrinsic degenerative
cascades might secondary reduce the level of inflammation in the CNS.
We additionally show that the protective effects of Laquinimod can
be visualized in vivo via PET-imaging using the TSPO tracer [18F]-GE-
180. As demonstrated in Fig. 2, [18F]-GE-180 radioligand uptake was
significantly increased in cuprizone+vehicle but not in cuprizone
+Laquinimod groups, compared to controls. The cellular source of
TSPO expression, and hence TSPO-ligand binding in the CNS of MS
patients is not entirely clear. While most studies suggest that TSPO is
predominantly expressed by activated microglia cells and in con-
sequence an increase in TSPO ligand binding is interpreted as microglia
activation (Abourbeh et al., 2012; Airas et al., 2015; Blume et al., 2018;
Klein et al., 2018; Mattner et al., 2013), various other cell types have
been shown to express TSPO as well, among astrocytes (Mattner et al.,
2011; Notter et al., 2018). In recent works, we and others were able to
demonstrate that in the cuprizone model an increase in TSPO expres-
sion is found in different cell types including microglia and astrocytes
(Nack et al., 2019; Zinnhardt et al., 2019). In line with this, on the
immunohistological level, we found reduced microglia and astrocyte
reactivity in Laquinimod compared to vehicle-treated mice which likely
contributes to the decreased tracer signal.
Fig. 3. Laquinimod ameliorates secondary immune cell recruitment.
(A) Clinical scores for CupEAE-Veh (black circle) and CupEAE-Laq (white triangle) mice. Quantification of the parameters day of disease onset (B), cumulative disease
scores (C) and maximum disease score. N=13 per experimental group. Differences were determined using Mann Whitney test. (E) Representative LFB/PAS stains of
the spinal cord. Arrowheads mark inflammatory infiltrates. (F) Extent of inflammatory demyelination in CupEAE-Veh (n= 10) and CupEAE-Laq (n=10) mice.
Differences were determined using Mann Whitney test. (G) Spatial distribution of perivascular infiltrates in the different treatment groups (H&E staining; black and
red dots from one independent observer each) at two brain levels (regions according to Sidman et al.). N=5 animals per experimental group. A representative
perivascular infiltrate is demonstrated in the center of the image. (H) Numbers of perivascular infiltrates in CupEAE-Veh and CupEAE-Laq groups. N= 13 per
experimental group. Differences were determined using Mann Whitney test. (I) Numbers of CD4+ lymphocytes in CupEAE-Veh and CupEAE-Laq groups. N=13 per
experimental group. Differences were determined using Mann Whitney test. (J) Representative anti-CD4 stained images to demonstrate Th-cell recruitment in
CupEAE-Veh and CupEAE-Laq mice. Lower parts of the image show the midline of the corpus callosum in higher magnification.
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Quinoline-3-carboxamide derivatives such as Laquinimod,
Tasquinimod or Paquinimod have shown immunomodulatory effects in
different pre-clinical animal models (Helmersson et al., 2013; Ott et al.,
2019). In a recent study it was shown that Laquinimod ameliorates EAE
by activating the aryl hydrocarbon receptor (Kaye et al., 2016). In the
same study the authors demonstrated by using bone marrow chimeras
that deletion of the aryl hydrocarbon receptor in the immune system
fully abrogates, whereas deletion within the CNS partially abrogates the
protective effect of Laquinimod in EAE. These results suggest that La-
quinimod has both, immunosuppressive and neuroprotective proper-
ties. In line with a proposed central protective effect, Laquinimod has
been shown to be protective in models of Huntington Disease (Garcia-
Miralles et al., 2017; Garcia-Miralles et al., 2019). As outlined in the
introduction section of this manuscript, two independent clinical stu-
dies demonstrated that Laquinimod is effective in suppressing devel-
opment of active lesions in relapsing-remitting MS (Comi et al., 2008;
Polman et al., 2005). Of note, the two phase 3 studies BRAVO and
ALLEGRO showed modest effects of Laquinimod on measures of focal
inflammatory disease activity, but more robust effects on reducing
brain atrophy and, possibly, disability worsening (Comi et al., 2012;
Vollmer et al., 2014). It is well known that the recruitment of peripheral
immune cells can lead to degeneration of neurons. For example, Siffrin
and colleagues nicely demonstrated that in EAE, the direct interaction
of MOG-specific Th17 and neuronal cells in demyelinating lesions is
associated with extensive axonal damage (Siffrin et al., 2010). Our re-
sults, however, show that an opposite scenario might as well be pos-
sible, that is: neurodegeneration can trigger the formation of new, focal
inflammatory lesions. Importantly, the clinical efficacy profile of La-
quinimod derived from the two relapsing-remitting MS studies, AL-
LEGRO and BRAVO, is distinctive and different from other disease
modifying treatments in MS because the reduction in disease progres-
sion is consistently larger than expected based on the relapse based
outcomes. We, thus, speculate that the neuroprotective effect of La-
quinimod (i.e., reduction in brain atrophy) in the BRAVO and ALLEGRO
phase 3 studies did, secondary, lead to the observed reduced in-
flammatory activity.
We would like to emphasize at that point that the reduced in-
flammatory activity in the forebrain of Laquinimod-treated Cup/EAE
mice is most likely not due to an immunosuppressive effect of
Laquinimod. As shown in Fig. 3, both surrogate markers for MOG35–55
induced autoimmunity, clinical EAE score and extent of inflammatory
demyelination in the spinal cord, was not significantly modulated by
Laquinimod treatment. This might, on the first view, be contradicting to
the previously reported immunosuppressive effects of Laquinimod in
EAE (Thone et al., 2012; Yang et al., 2004; Zou et al., 2002). However,
in the current study Laquinimod treatment was terminated two weeks
prior to active EAE induction (see supplementary Fig. 1). We, thus,
assume that two weeks were enough to reduce Laquinimod levels in the
body to an extent where it is not immunosuppressive any more. Indeed,
results of clinical studies suggest that high doses of Laquinimod are
required to exert its full anti-inflammatory activity (Comi et al., 2008).
Furthermore, pharmacokinetic studies in mice showed a relatively short
half-time of Laquinimod (Brunmark et al., 2002). In particular, oral
administration of 5mg/kg to female SJL/N mice led to a peak plasma
concentration of 25 μM. As soon as 15 h post application, Laquinimod's
plasma concentration was lower than 2 μM. As demonstrated in Fig. 2,
the cumulative disease score tended to be lower in Laquinimod-treated
compared to vehicle-treated CupEAE mice. However, statistical com-
parison of both groups revealed no significant difference (p=0.2814).
It might principally be that too few mice were included to determine
whether Laquinimod indeed suppresses anti-MOG35–55 immune re-
sponses. In other words, our study could lack sufficient statistical power
to detect a potential Laquinimod effect on the cumulative disease score.
Thus, we cannot rule out a minor immunosuppressive effect of Laqui-
nimod in Cup/EAE mice, but such a minor effect, if present, would not
explain the pronounced protective effect of Laquinimod on the level of
the forebrain in Cup/EAE mice.
In summary, this study clearly illustrates that amelioration of a
primary brain-intrinsic degenerative process secondary halts peripheral
immune cell recruitment and, in consequence, inflammatory lesion
development. These findings have important consequences for the in-
terpretation of the results of clinical studies.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nbd.2019.104675.
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